A nerve growth-promoting agent associated with mouse Sarcomas 37 and 180 has previously been demonstrated in vitro and in vivo (3, 8, 15–17). Twenty additional tumors were screened with in vivo technics.
Tumors were implanted and grown in the embryonic chick. From 1,048 experiments, 464 embryos of 3–17 days of incubation were obtained. One hundred and forty embryos were sectioned.
In representative cases selected for study, the grafts were located unilaterally at the base of the hind limb and accessible to lumbosacral nerves.
Spinal and sympathetic ganglia adjacent to undifferentiated mouse sarcoma grafts (274, T241, MA387, 653, 637, MCI) supplied nerves to grafts and were within a range 1.50–3.00 × larger than contralateral ganglia. In embryos with 274 allantoic grafts, neuromatous formations were found in walls of veins, and the mesonephros, gonads, adrenals, and thyroid were hyperneurotized.
Spinal and sympathetic ganglia of embryos with mouse spindle-cell sarcoma (Ds4) or rat sarcomas (Wc, S6, Fs) were within an average range of 1.12–1.25× larger than contralateral. Carcinoma grafts failed to elicit nerve growth responses.
The ability of tumors to infiltrate or form metastatic centers had no relationship to the nerve growth agent. Likewise, host specificity or nonspecificity could not be associated with this phenomenon.
Of the various tumors studied and presented in this paper, only mouse sarcomas were strongly positive in nerve growth effects; rat sarcomas produced mild effects. All carcinomas regardless of origin were negative. The biochemical basis for producing growth acceleration of spinal and sympathetic ganglia in the chick is probably very similar to that demonstrated with Sarcomas 37 and 180.
This investigation was supported in part by research grants from the National Cancer Institute of the Public Health Service (C-2794 M & G) and the Damon Runyon Memorial Fund (DRG-378).